- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
Angiotensin-converting enzyme (ACE) inhibitors are a group of medicines that includes the drug lisinopril. Heart failure and hypertension are its two main indications for use. Lisinopril lowers blood pressure and improves blood flow to the heart by relaxing the blood vessels.
With or without food, lisinopril is typically taken once day. It's crucial to take lisinopril precisely as directed by your physician. Without first talking to your doctor, you shouldn't stop taking lisinopril.
Lisinopril's side effects can include nausea, vomiting, dry cough, fatigue, headache, and dizziness. Consult your doctor if you suffer any negative effects while taking lisinopril.
Other medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), potassium supplements, and diuretics, may interact with lisinopril.
Before starting lisinopril, it's crucial to let your doctor know about all the drugs you're taking, including over-the-counter medicines and dietary supplements.
Global lisinopril market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Because ACE inhibitors like lisinopril are said to raise levels of ACE-2, the protein that the SARs-CoV-2 virus attaches to, they may enhance the likelihood of COVID-19 complications.
The risk of a heart attack or stroke, however, surpasses the hypothetical possibility of worse COVID-19 results by a significant margin[1]. There is no proof, according to Drugs.com, that ACE inhibitors raise the risk of COVID-19 complications.
Another possible explanation for why those with high blood pressure are more prone to get pulmonary side and effects from COVID-19 is an overactive renin-angiotensin system. Nevertheless, during the COVID-19 pandemic, quitting ACE inhibitor use has a higher risk than continuing it.
In conclusion, the hypothesis that ACE medications enhance the incidence of COVID-19 problems is unfounded.
The risk of a heart attack or stroke and hemorrhage from stopping these medications outweighs the potential risk of worse COVID-19 outcomes by a significant margin.
Another factor that may contribute to the increased risk of pulmonary COVID-19 problems in those with high blood pressure is the possibility of an overactive renin-angiotensin system.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in the Industry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2023 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2023 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2025 Mobility Foresights Admin Pvt Ltd. All rights reserved.